TICKERNERD
Menu
PCVXPCVXHealthcare · Biotechnology

PCVX Stock Forecast: Vaxcyte, Inc. Price Predictions for 2026-2027

Last close, 3 Sept 2026
$61
−0.65% on the day

The 11 Wall Street analysts covering Vaxcyte, Inc. hold a median 12-month price target of $110 — +79.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 53 of 100 as at 2 Sept 2026 — in the upper half.

Market cap
$9.2B
Ticker Nerd rank
53 / 100
Median analyst target
$110
Analysts covering
11
Revenue$0.0
Operating income−$302.8M
Net income−$284.3M
Free cash flow−$237.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.0%
1M
+14.3%
YTD
+32.6%
1Y
+90.6%
From 52W high
−3.3%
From 52W low
+98.1%
$31
$63
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PCVX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Vaxcyte, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 2 Sept 2026
53 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
89
Momentum
85
Value
79
Quality
72
Accruals
62
Revisions
48
Issuance
25
Growth
23
Size
17

Volatility (89): The share price has been relatively steady.

Growth (23): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (17): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PCVX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PCVX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150Oct 25Jan 26Apr 26Jul 26PCVXHigh $163Median $110Low $67

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
10 Buy1 Hold0 Sell
Low $67Median $110High $163

The green dot is the last close — the median target sits +79.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
26 Feb 2026BTIGMaintainsBuy—
26 Feb 2026BTIGMaintainsBuy$85 → $89
2 Feb 2026GuggenheimReiteratesBuy—
10 Nov 2025BTIGReiteratesBuy—
16 Oct 2025BTIGMaintainsBuy—
12 Sept 2025Goldman SachsInitiatesNeutral—
22 Apr 2025Cantor FitzgeraldInitiatesOverweight—
8 Apr 2025NeedhamReiteratesBuy—
1 Apr 2025B of A SecuritiesMaintainsBuy—
1 Apr 2025Goldman SachsMaintainsBuy—
1 Apr 2025NeedhamMaintainsBuy—
12 Mar 2025GuggenheimReiteratesBuy—
26 Feb 2025GuggenheimReiteratesBuy—
26 Feb 2025NeedhamReiteratesBuy—
24 Feb 2025BTIGReiteratesBuy—
11 Feb 2025NeedhamReiteratesBuy—
24 Dec 2024BTIGReiteratesBuy—
20 Dec 2024Goldman SachsInitiatesBuy—
6 Nov 2024Cantor FitzgeraldReiteratesOverweight—
6 Nov 2024NeedhamReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PCVX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PCVX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 3 Sept 2026, Vaxcyte, Inc. returned +90.6% against +21.4% for the S&P 500, dividends included.

PCVX vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180200Oct 25Jan 26Apr 26Jul 26PCVXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PCVX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
0
Fundamentals

Vaxcyte, Inc. (PCVX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−10.9×

Cheaper than 93% of US stocks

Price / sales
—
Price / book
3.2×

Cheaper than 33% of US stocks

EV / EBITDA
−6.8×

Cheaper than 81% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−36.5%

Higher than 25% of US stocks

Return on assets
−22.6%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Vaxcyte, Inc. (PCVX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Vaxcyte, Inc. has a market value of $9.2B and an enterprise value of $7.8B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$1.1B.

  • Free cash flow in the twelve months to 30 June 2026: −$921.1M.

  • Shares outstanding: 144.8M.

  • Trailing P/E: −10.9×; forward P/E: −8.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Vaxcyte, Inc. employs 507 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 3 Sept 2026

Data provided by Twelve Data

Peers

PCVX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PCVXVaxcyte, Inc.$9.2B
53
CRNXCrinetics Pharmaceuticals, Inc.$8.7B
—
TWSTTwist Bioscience Corp.$8.6B
62
TGTXTG Therapeutics, Inc.$9.0B
68
IBRXImmunityBio, Inc.$8.3B
52
PTGXProtagonist Therapeutics, Inc.$9.3B
97
IMVTImmunovant, Inc.$8.0B
41

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Vaxcyte, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PCVX news & analysis

Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data

GlobeNewsWire · 3 Sept 2026positive

Vaxcyte announced the appointment of Luis Jodar, Ph.D., former Pfizer Chief Medical Officer for Vaccines and Infectious Diseases, as its Chief Medical Officer, along with the naming of a new Chief Legal Officer. The company also narrowed its guidance for the expected topline data from its VAX-31 OPUS-1 trial.

Why it matters — A PCVX watcher would care because the new Chief Medical Officer brings deep experience with pneumococcal conjugate vaccines Prevnar 13 and Prevnar 20, and the narrowed timeline for key VAX-31 topline data provides greater clarity on a major upcoming catalyst.

Vaxcyte to Participate in Upcoming Investor Conferences

GlobeNewsWire · 27 Aug 2026neutral

Vaxcyte announced that its management will participate in fireside chats and host one-on-one meetings at upcoming investor conferences. The announcement was made by the clinical-stage vaccine innovation company on August 27, 2026.

Why it matters — PCVX watchers may see this as an opportunity for the company to present its clinical-stage vaccine pipeline to the investment community.

If You Followed Seth Klarman Into Vaxcyte in May, He Was Already Long Gone

24/7 Wall Street · 16 Aug 2026negative

Seth Klarman's Baupost Group eliminated its entire stake in Vaxcyte during the June quarter, as disclosed in its 13F filing on August 13, 2026. The fund had previously been a notable investor in the company.

Why it matters — PCVX watchers would care because the complete exit by a high-profile value investor may signal reduced institutional confidence and a change in the company's shareholder base.

Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 5 Aug 2026neutral

Vaxcyte reported its second quarter 2026 financial results and provided a business update. The company expects topline data from its VAX-31 adult Phase 3 OPUS-1 trial in the fourth quarter of 2026, with OPUS-2 and OPUS-3 results in the first half of 2027, initiated a Phase 1 study of VAX-A1 for Group A Streptococcus, and reported approximately $2.5 billion in cash as of June 30, 2026.

Why it matters — PCVX watchers would track the upcoming timelines for VAX-31 Phase 3 and VAX-A1 Phase 1 data, along with the company's cash position, as markers of pipeline progress.

FAQ

Frequently asked questions about PCVX stock

What is the PCVX stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Vaxcyte, Inc. have a median 12-month price target of $110, with estimates ranging from $67 to $163. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PCVX stock a buy right now?

Of the 11 analysts covering Vaxcyte, Inc., 10 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vaxcyte, Inc. 53 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PCVX?

As at 2 Sept 2026, Vaxcyte, Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (89 of 100).

Will PCVX stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +79.8% from the last close, and Ticker Nerd's factor model ranks Vaxcyte, Inc. 53 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PCVX stock forecast for 2030?

No analyst covering Vaxcyte, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PCVX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $67 to $163 over the next 12 months.

How has PCVX stock performed over the past year?

Vaxcyte, Inc. returned +90.6% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Vaxcyte, Inc. do?

Vaxcyte Inc. is a clinical-stage vaccine company focused on developing next-generation vaccines for bacterial infectious diseases.

What is the latest news on PCVX?

The most recent item we track (GlobeNewsWire, 3 Sept 2026): "Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data". Vaxcyte announced the appointment of Luis Jodar, Ph.D., former Pfizer Chief Medical Officer for Vaccines and Infectious Diseases, as its Chief Medical Officer, along with the naming of a new Chief Legal Officer. The company also narrowed its guidance for the expected topline data from its VAX-31 OPUS-1 trial.

Company

About Vaxcyte, Inc.

Vaxcyte Inc. is a clinical-stage vaccine company focused on developing next-generation vaccines for bacterial infectious diseases. The company uses its proprietary cell-free protein synthesis platform to design and produce optimized protein carriers and antigens, supporting the creation of conjugate and protein-based vaccine candidates. Its current pipeline centers on pneumococcal programs aimed at preventing invasive pneumococcal disease, along with additional candidates targeting other serious bacterial conditions. Vaxcyte Inc. operates in the biotechnology and infectious disease markets, where its work addresses areas with significant unmet medical need. Based in San Carlos, California, the company is known for its emphasis on broad-spectrum vaccine design and advanced manufacturing methods that differ from conventional cell-based approaches.

CEO Mr. Grant E. Pickering M.B.A. · 507 employees · United States · https://vaxcyte.com